This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toogood, A. A. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Toogood, A. A. Articles by Shalet, S. M.

Elderly Patients with Adult-Onset Growth Hormone Deficiency Are Not Osteopenic¹

Department of Endocrinology, Christie Hospital National Health Service Trust, Manchester, United Kingdom M20 4BX; the Department of Diagnostic Radiology, University of Manchester (J.E.A.), Manchester, United Kingdom M13 9PT; and the University Department of Geriatric Medicine, South Manchester University Hospital Trust (P.A.O.), Manchester, United Kingdom M20 8LR

Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital National Health Service Trust, Wilmslow Road, Manchester, United Kingdom M20 4BX.

The age-related decline in GH secretion has been implicated in the development of osteoporosis. GH-deficient adults show a significant reduction in bone mineral density (BMD), which is greater in those with childhood-onset GH deficiency than in those with GH deficiency occurring in adult life. To determine whether GH deficiency in late adult life causes a reduction in BMD beyond the decline observed with increasing age, we studied 21 patients over the age of 60 yr with GH deficiency caused by organic pituitary disease and 23 controls of similar age and sex distribution and BMI. Dual energy x-ray absorptiometry was used to determine total bone mass and BMD at the hip and in the lumbar spine. Serum osteocalcin was determined in all subjects and urinary deoxypyridinoline/creatinine ratio in 19 patients and 21 controls. The median (range) known duration of GH deficiency in the patients was 8 yr (range, 4–41 yr).

The median (range) total bone mass was 2774 g (range, 1534–3734) in the patients and 2717 g (range, 1235–3549) in the controls (P = 0.42). Specific measurements of BMD made at L2–L4, the right femoral neck, the right femoral trochanter, and Ward’s triangle were 1.234 (range, 0.778–1.507) vs. 1.144 g/cm² (range, 0.809–1.466; P = 0.48), 0.921 (range, 0.605–1.372) vs. 0.96 g/cm² (range, 0.534–1.315; P = 0.62), 0.92 (range, 0.523–1.229) vs. 0.915 g/cm² (range, 0.353–1.313; P = 0.68), and 0.773 (range, 0.408–1.289) vs. 0.806 g/cm² (range, 0.353–1.154; P = 0.81) in the patients and controls, respectively. The median (range) serum osteocalcin was 11.5 (range, 3.6–23.0) vs. 15.1 ng/mL (range, 0.7–40.5; P = 0.019) in the patients and controls, respectively. The median (range) deoxypyridinoline cross-links/creatinine ratio was 3.5 µmol/mol (range, 0.8–8.3) in the patients and 4.9 µmol/mol (range, 3.0–9.7) in the controls (P 0.038). There was a significant correlation between serum insulin-like growth factor I and total bone mass in the controls, but not in the patients.

These data demonstrate that BMD is not significantly altered in GH-deficient adults over the age of 60 yr. Markers of bone formation and resorption are decreased, however, suggesting that bone turnover is reduced. Further studies are required to determine whether the reduction in bone turnover in these patients is of benefit.

This article has been cited by other articles:

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				K. Stochholm, T. Laursen, A. Green, P. Laurberg, M. Andersen, L. O. Kristensen, U. Feldt-Rasmussen, J. S. Christiansen, M. Frydenberg, and C. H. Gravholt Morbidity and GH deficiency: a nationwide study. Eur. J. Endocrinol., April 1, 2008; 158(4): 447 - 457. [Abstract] [Full Text] [PDF]

				G Gotherstrom, B-A Bengtsson, I Bosaeus, G Johannsson, and J Svensson Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 55 - 64. [Abstract] [Full Text] [PDF]

				C. Franco, G. Johannsson, B.-A. Bengtsson, and J. Svensson Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4408 - 4414. [Abstract] [Full Text] [PDF]

				R. D. Murray, J. E. Adams, and S. M. Shalet A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 432 - 438. [Abstract] [Full Text] [PDF]

				H. D. White, A. M. Ahmad, B. H. Durham, A. Patwala, P. Whittingham, W. D. Fraser, and J. P. Vora Growth Hormone Replacement Is Important for the Restoration of Parathyroid Hormone Sensitivity and Improvement in Bone Metabolism in Older Adult Growth Hormone-Deficient Patients J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3371 - 3380. [Abstract] [Full Text] [PDF]

				S. V Haijma, P S. van Dam, W. R de Vries, I. Maitimu-Smeele, C. Dieguez, F. F Casanueva, and H. P F Koppeschaar The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men Eur. J. Endocrinol., April 1, 2005; 152(4): 575 - 580. [Abstract] [Full Text] [PDF]

				R. D. Murray, B. Columb, J. E. Adams, and S. M. Shalet Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1124 - 1130. [Abstract] [Full Text] [PDF]

				N. R. Biermasz, N. A. T. Hamdy, Y. J. H. Janssen, and F. Roelfsema Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3079 - 3085. [Abstract] [Full Text] [PDF]

				R. Fernholm, M. Bramnert, E. Hägg, A. Hilding, D. J. Baylink, S. Mohan, and M. Thorén Growth Hormone Replacement Therapy Improves Body Composition and Increases Bone Metabolism in Elderly Patients with Pituitary Disease J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4104 - 4112. [Abstract] [Full Text]

				G. Ravaglia, P. Forti, F. Maioli, B. Nesi, L. Pratelli, D. Cucinotta, L. Bastagli, and G. Cavalli Body Composition, Sex Steroids, IGF-1, and Bone Mineral Status in Aging Men J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2000; 55(9): 516M - 521. [Abstract] [Full Text]

				S. M. Shalet Growth Hormone (GH) Replacement Is Not Justified for All Adults with GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 937 - 939. [Full Text]

				B. M. K. Biller, G. Sesmilo, H. B. A. Baum, D. Hayden, D. Schoenfeld, and A. Klibanski Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 970 - 976. [Abstract] [Full Text]

				A. Colao, A. Cuocolo, C. Di Somma, G. Cerbone, A. M. Della Morte, E. Nicolai, R. Lucci, M. Salvatore, and G. Lombardi Impaired Cardiac Performance in Elderly Patients with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3950 - 3955. [Abstract] [Full Text]

				A. A. Toogood and S. M. Shalet Growth Hormone Replacement Therapy in the Elderly with Hypothalamic-Pituitary Disease: A Dose-Finding Study J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 131 - 136. [Abstract] [Full Text]

				Y. J. H. Janssen, N. A. T. Hamdy, M. Frölich, and F. Roelfsema Skeletal Effects of Two Years of Treatment with Low Physiological Doses of Recombinant Human Growth Hormone (GH) in Patients with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2143 - 2148. [Abstract] [Full Text]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				T. Bianda, Y. Glatz, R. Bouillon, E. R. Froesch, and C. Schmid Effects of Short-Term Insulin-Like Growth Factor-I (IGF-I) or Growth Hormone (GH) Treatment on Bone Metabolism and on Production of 1,25-Dihydroxycholecalciferol in GH-Deficient Adults J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 81 - 87. [Abstract] [Full Text]